These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

583 related articles for article (PubMed ID: 19025933)

  • 21. Outcomes of acute rejection after interferon therapy in liver transplant recipients.
    Saab S; Kalmaz D; Gajjar NA; Hiatt J; Durazo F; Han S; Farmer DG; Ghobrial RM; Yersiz H; Goldstein LI; Lassman CR; Busuttil RW
    Liver Transpl; 2004 Jul; 10(7):859-67. PubMed ID: 15237369
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factors influencing the progression of fibrosis in patients with recurrent hepatitis C after liver transplantation under antiviral therapy: a retrospective analysis of 939 liver biopsies in a single center.
    Walter T; Dumortier J; Guillaud O; Hervieu V; Scoazec JY; Boillot O
    Liver Transpl; 2007 Feb; 13(2):294-301. PubMed ID: 17256784
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Response to combination therapy in hepatitis virus C genotype 2 and 3.
    Khan AA; Sarwar S
    J Coll Physicians Surg Pak; 2009 Aug; 19(8):473-7. PubMed ID: 19651007
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of diet on liver fibrosis and on response to interferon therapy in patients with HCV-related chronic hepatitis.
    Loguercio C; Federico A; Masarone M; Torella R; Blanco Cdel V; Persico M
    Am J Gastroenterol; 2008 Dec; 103(12):3159-66. PubMed ID: 18786125
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of fibrosis progression on clinical outcome in patients treated for post-transplant hepatitis C recurrence.
    Dhanasekaran R; Sanchez W; Mounajjed T; Wiesner RH; Watt KD; Charlton MR
    Liver Int; 2015 Nov; 35(11):2433-41. PubMed ID: 26058570
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Review article: predicting response in hepatitis C virus therapy.
    Mihm U; Herrmann E; Sarrazin C; Zeuzem S
    Aliment Pharmacol Ther; 2006 Apr; 23(8):1043-54. PubMed ID: 16611264
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term monitoring of platelet count, as a non-invasive marker of hepatic fibrosis progression and/or regression in patients with chronic hepatitis C after interferon therapy.
    Taniguchi H; Iwasaki Y; Fujiwara A; Sakaguchi K; Moriya A; Yu PC; Takaki A; Fujioka S; Shimomura H; Shiratori Y
    J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 2):281-7. PubMed ID: 16460487
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is serum uric acid a predictive factor of response to IFN-treatment in patients with chronic hepatitis C infection?
    Pellicano R; Puglisi G; Ciancio A; Balzola F; Saracco G; Ciccone G; Baldi I; Abate ML; Smedile A; Rizzetto M
    J Med Virol; 2008 Apr; 80(4):628-31. PubMed ID: 18297716
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Delayed onset of severe hepatitis C-related liver damage following liver transplantation: a matter of concern?
    Berenguer M; Aguilera V; Prieto M; Carrasco D; Rayón M; San Juan F; Landaverde C; Mir J; Berenguer J
    Liver Transpl; 2003 Nov; 9(11):1152-8. PubMed ID: 14586875
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience.
    Coilly A; Roche B; Dumortier J; Leroy V; Botta-Fridlund D; Radenne S; Pageaux GP; Si-Ahmed SN; Guillaud O; Antonini TM; Haïm-Boukobza S; Roque-Afonso AM; Samuel D; Duclos-Vallée JC
    J Hepatol; 2014 Jan; 60(1):78-86. PubMed ID: 23994384
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preemptive antiviral treatment for hepatitis C virus after living donor liver transplantation.
    Sugawara Y; Tamura S; Yamashiki N; Kaneko J; Aoki T; Sakamoto Y; Hasegawa K; Kokudo N
    Transplant Proc; 2012 Apr; 44(3):791-3. PubMed ID: 22483497
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults.
    Sulkowski MS; Mehta SH; Torbenson MS; Higgins Y; Brinkley SC; de Oca RM; Moore RD; Afdhal NH; Thomas DL
    AIDS; 2007 Oct; 21(16):2209-16. PubMed ID: 18090048
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Time course of insulin resistance during antiviral therapy in non-diabetic, non-cirrhotic patients with genotype 1 HCV infection.
    Petta S; Cammà C; Di Marco V; Cabibi D; Ciminnisi S; Caldarella R; Licata A; Massenti MF; Marchesini G; Craxì A
    Antivir Ther; 2009; 14(5):631-9. PubMed ID: 19704165
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of nonalcoholic fatty liver disease and the metabolic syndrome on progression of fibrosis in patients with recurrent HCV after liver transplantation.
    Mindikoglu AL; Regev A; Casanova-Romero PY; Bejarano PA; Martinez EJ; Tzakis AG; Schiff ER
    Transplant Proc; 2006 Jun; 38(5):1440-4. PubMed ID: 16797327
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Flexible and individualized treatment to achieve sustained viral response for recurrent hepatitis C in liver transplant recipients.
    Lee WC; Wu TJ; Chou HS; Lee CF; Chan KM; Cheng SS
    J Viral Hepat; 2010 Nov; 17(11):770-7. PubMed ID: 20337926
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term histological effects of preemptive antiviral therapy in liver transplant recipients with hepatitis C virus infection.
    Kuo A; Tan V; Lan B; Khalili M; Feng S; Roberts JP; Terrault NA
    Liver Transpl; 2008 Oct; 14(10):1491-7. PubMed ID: 18825708
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Retreatment of patients with chronic hepatitis C].
    Ostojić R
    Acta Med Croatica; 2005; 59(5):447-51. PubMed ID: 16381242
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment.
    Gopal K; Johnson TC; Gopal S; Walfish A; Bang CT; Suwandhi P; Pena-Sahdala HN; Clain DJ; Bodenheimer HC; Min AD
    Hepatology; 2006 Aug; 44(2):335-40. PubMed ID: 16871569
    [TBL] [Abstract][Full Text] [Related]  

  • 39. α-fetoprotein levels after interferon therapy predict regression of liver fibrosis in patients with sustained virological response.
    Tachi Y; Hirai T; Ishizu Y; Honda T; Kuzuya T; Hayashi K; Ishigami M; Goto H
    J Gastroenterol Hepatol; 2016 May; 31(5):1001-8. PubMed ID: 27123974
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of low accelerating dose regimen of interferon/ribavirin antiviral therapy in patients with hepatitis C virus recurrence after liver transplantation.
    Su H; Liu Z; Sun Y; Li H; Zhou S; Zhou X; Gao Y; Tang R; Zhang D; Zhang M
    Ann Transplant; 2015 May; 20():263-8. PubMed ID: 25975740
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.